{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T11:33:10Z","timestamp":1648812790637},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00106-022-01149-x","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T22:02:22Z","timestamp":1646431342000},"page":"252-257","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neue Daten vom ASCO-Kongress 2021 zum Thema \u201echirurgische Therapie\u201c"],"prefix":"10.1007","volume":"70","author":[{"given":"Stephan","family":"Hackenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thien An","family":"Doung Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"issue":"15","key":"1149_CR1","doi-asserted-by":"publisher","first-page":"6010","DOI":"10.1200\/JCO.2021.39.15_suppl.6010","volume":"39","author":"RL Ferris","year":"2021","unstructured":"Ferris\u00a0RL, Flamand\u00a0Y, Weinstein\u00a0GS et al (2021) Updated report of a\u00a0phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311). J\u00a0Clin Oncol 39(15):6010\u20136010","journal-title":"J Clin Oncol"},{"issue":"15","key":"1149_CR2","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1200\/JCO.2020.38.15_suppl.6500","volume":"38","author":"RL Ferris","year":"2020","unstructured":"Ferris\u00a0RL, Flamand\u00a0Y, Weinstein\u00a0GS et al (2020) Transoral robotic surgical resection followed by randomization to low-or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311). J\u00a0Clin Oncol 38(15):6500\u20136500","journal-title":"J Clin Oncol"},{"key":"1149_CR3","doi-asserted-by":"crossref","unstructured":"Ferris RL, Flamand Y, Weinstein GS et al (2021) Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in Resectable p16+ locally advanced Oropharynx cancer: an ECOG-ACRIN cancer research group trial (E3311). J\u00a0Clin Oncol 40(2):138\u2013149","DOI":"10.1200\/JCO.21.01752"},{"issue":"15","key":"1149_CR4","doi-asserted-by":"publisher","first-page":"6066","DOI":"10.1200\/JCO.2021.39.15_suppl.6066","volume":"39","author":"C Resteghini","year":"2021","unstructured":"Resteghini\u00a0C, Castelnuovo\u00a0P, Nicolai\u00a0P et al (2021) The SINTART 1\u00a0study: A phase II trial of induction chemotherapy (IC), surgery, photon-, proton- and cabon ion-based radiotherapy (RT) in locally advanced operable sinonasal epithelial tumors patients (pts). J\u00a0Clin Oncol 39(15):6066\u20136066","journal-title":"J Clin Oncol"},{"issue":"15","key":"1149_CR5","first-page":"TPS6093","volume":"39","author":"S Yenzen Lai","year":"2021","unstructured":"Yenzen Lai\u00a0S, Torres-Saavedra\u00a0PA, Dunlap\u00a0NE et al (2021) NRG Oncology HN006: Randomized phase II\/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer. J\u00a0Clin Oncol 39(15):TPS6093","journal-title":"J Clin Oncol"},{"issue":"15","key":"1149_CR6","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1200\/JCO.2021.39.15_suppl.6054","volume":"39","author":"A Kumar","year":"2021","unstructured":"Kumar\u00a0A, Cherry\u00a0DR, Voora\u00a0RS et al (2021) Transoral robotic surgery for human papillomavirus-associated oropharynx squamous cell carcinoma: Recurrence and survival in the Veterens Affairs health system. J\u00a0Clin Oncol 39(15):6054","journal-title":"J Clin Oncol"},{"issue":"15","key":"1149_CR7","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1200\/JCO.2021.39.15_suppl.6047","volume":"39","author":"D Basu","year":"2021","unstructured":"Basu\u00a0D, Shimunov\u00a0D, Cohen\u00a0RB et\u00a0al (2021) Outcomes and prediction of lethal recurrence after transoral robotic surgery for HPV+ head and neck cancer. J\u00a0Clin Oncol 39(15):6047","journal-title":"J Clin Oncol"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-022-01149-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-022-01149-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-022-01149-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T05:20:05Z","timestamp":1648531205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-022-01149-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1149"],"URL":"https:\/\/doi.org\/10.1007\/s00106-022-01149-x","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"value":"0017-6192","type":"print"},{"value":"1433-0458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"assertion":[{"value":"17 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Hackenberg: Advisory Board f\u00fcr MSD, BMS und Sanofi, Vortragshonorare von Merck Serono, MSD, BMS, T.A.\u00a0Doung Dinh und M.\u00a0Goncalves geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}